{"id":"W2896936188","doi":"10.1016/j.ejca.2018.09.020","title":"Letter comments on a published article in the New England Journal of Medicine","year":2018,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Seattle Genetics; Takeda Pharmaceuticals U.S.A.","keywords":"Brentuximab vedotin; ABVD; Dacarbazine; Vinblastine; Medicine; Bleomycin; Oncology; Internal medicine; Antibody-drug conjugate; Hodgkin lymphoma; Lymphoma; Vincristine; Chemotherapy; Immunology; Antibody; Monoclonal antibody; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001766524,0.0007913932,0.001413066,0.0009811457,0.003040031,0.003310569,0.001450718,0.03681957,0.0191438],"category_scores_gemma":[0.02045871,0.0006016851,0.001040279,0.0006597998,0.001727109,0.002366548,0.001046513,0.01945217,0.01105423],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003654439,"about_ca_system_score_gemma":0.002593108,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003827139,"about_ca_topic_score_gemma":0.005867243,"domain_scores_codex":[0.9975601,0.0006720164,0.0002683065,0.0002835346,0.0007654793,0.0004505169],"domain_scores_gemma":[0.9941509,0.002698106,0.0006245365,0.0001397183,0.001216035,0.001170599],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001036895,0.00004929881,0.0009972908,0.00004095704,0.00001668339,0.004204224,0.00009562822,0.00006041224,0.000113796,0.001038994,0.9892658,0.004013151],"study_design_scores_gemma":[0.0001801276,0.0001233338,0.002460886,0.0003671994,0.00005272967,0.006270929,0.0006979341,0.0007008094,0.0003484615,0.005030788,0.9836866,0.00008017887],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0007087694,0.0006184768,0.00005790663,0.9621337,0.03127041,0.00001337569,0.00009143868,0.00003894384,0.005066948],"genre_scores_gemma":[0.009735195,0.001299194,0.0002022796,0.8958746,0.06812554,0.00004506647,0.00009846652,0.00005453585,0.02456509],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.03681957,"threshold_uncertainty_score":0.06404233,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02863467266914706,"score_gpt":0.2940017579017004,"score_spread":0.2653670852325533,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}